Location of Repository

A biomarker guided approach in heart failure

By Mark Abela

Abstract

Heart failure is one of the commonest diagnoses presenting to physicians in the community or hospital care. Symptoms are often subjective, with clinicians having to rely on clinical assessment and radiological imaging to manage these patients. Treatment is often symptomatic with no clear therapeutic goals as yet identified. To date, there are no objective measures to diagnose, predict, prognosticate or guide therapy in compensated and decompensated heart failure, which is why a novel biomarker guided management approach is gaining so much momentum in the clinical community. This review encompasses recent data on this new approach and details on the potential clinical benefits of the most widely studied cardiac biomarkers currently available

Topics: Heart failure -- Symptoms, Diagnosis -- Biological Markers, Heart failure -- Treatment
Publisher: Malta Medical Journal
Year: 2014
OAI identifier: oai:www.um.edu.mt:123456789/1664
Provided by: OAR@UM

Suggested articles

Preview

Citations

  1. Biomarker-guided therapy in chronic heart failure: a metaanalysis of randomized controlled trials. doi
  2. Biomarker-guided therapy in heart failure: A forum of unified strategies. doi
  3. Biomarkers and Diagnostics in heart failure. doi
  4. Biomarkers of Cardiovascular disease molecular basis and practical considerations. doi
  5. Cardiac biomarkers: new tools for heart failure management,” Cardiovascular diagnosis and therapy.
  6. Distribution and clinical correlates of the interluekin receptor family member soluble ST2 in the Framingham Heat Study. Clinical chemistry. doi
  7. Galectin-3 marks activated marcrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
  8. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. doi
  9. Galectin-3, cardiac structure and function, an dlong-term mortality in patients with acutely decompensated heart failure. European journal of Heart Failure. doi
  10. Growth differentiation factor 15 in different stages of HF: potential screening implications. doi
  11. Growth differentiation factor-1 improves risk stratification in STsegment elevatiion myocardial infarction.
  12. Mid-region prohormone markers for diagnosis and prognosis in acute dyspnoea: results from the BACH (Biomarkers in Acute HF) trial.
  13. N-Terminal Pro-B-Type Natriuretic Peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicentre IMPROVECHF Study,” Circulation. doi
  14. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. doi
  15. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. doi
  16. (2010). Prognostic value of galectin-3, a novel marker of fibrosis in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiology. doi
  17. Soluble concentrations of the interluekin receptor family member ST2 and B-Blocker therapy in Chronic Heart Failure. Circ Heart Failure. doi
  18. State of the art: Using natriuretic peptide levels in clinical practice. European heart journal of heart failure. doi
  19. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3 and apelin for the evaluation of patients with acute heart failure. doi
  20. Veldhuisen, Galectin-3: a novel mediator of heart failure development and progression. European journal of heart failure. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.